What does this research mean for the field?

Omission of hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of colorectal peritoneal metastases does not result in significant morbidity and provides equivalent short-term oncologic benefits compared to treatment with HIPEC. Novelty: ClaimNovelty.CONFIRMATORY. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

This research aims to evaluate the effects of omitting hyperthermic intraperitoneal chemotherapy (HIPEC) during treatment for colorectal peritoneal metastases (CPM).

February 19, 2026Open Access

Impact of Omission of Hyperthermic Intraperitoneal Chemotherapy for Treatment of Colorectal Peritoneal Metastases

KIKyuseok Im SYSteven YoshinagaKaiser Permanente West Los Angeles Medical Center ALAnna LeungKaiser Permanente West Los Angeles Medical Center

Key Points

This research aims to evaluate the effects of omitting hyperthermic intraperitoneal chemotherapy (HIPEC) during treatment for colorectal peritoneal metastases (CPM).
Evaluated short-term oncologic outcomes after cytoreductive surgery (CRS) with and without HIPEC.
Compared morbidity associated with each treatment approach.
Analyzed long-term benefits of HIPEC, if any.
Omission of HIPEC did not result in significant morbidity.
Short-term oncologic benefits were found to be equivalent between groups.
Long-term benefits of HIPEC remain uncertain.

Abstract

CRS with mitomycin-HIPEC can be considered for treatment of CPM without significant morbidity and equivalent short-term oncologic benefits. However, the long-term benefit of HIPEC remains unclear.

اسأل الذكاء الاصطناعي

Bookmark

View Full Paper

Cite This Study

Im et al. (Tue,) studied this question.

synapsesocial.com/papers/6996a879ecb39a600b3ef30e https://doi.org/https://doi.org/10.7812/tpp/25.129

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

اسأل الذكاء الاصطناعي

Bookmark

View Full Paper